{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "PART 184 -- DIRECT FOOD SUBSTANCES AFFIRMED AS GENERALLY RECOGNIZED AS SAFE" in comments (approximate match)
Status:
First approved in 1962
Class:
MIXTURE
Status:
First approved in 1951
Class:
MIXTURE
Status:
US Previously Marketed
Source:
DEPINAR by ARMOUR PHARM
(1960)
Source URL:
First marketed in 1921
Class:
MIXTURE
Targets:
Tannic acid (TA) is a naturally occurring plant-derived polyphenol found in several herbaceous and woody plants, wines and a broad selection of teas. TA has strong antioxidant/free radical scavenging, anti-inflammatory, anti-viral/bacterial, and anti-carcinogenic properties. The neuroprotective effects of TA against Alzheimer’s disease (AD) have been shown in several in vitro and in vivo models of AD. Evidence suggests that TA is a natural inhibitor of β-secretase (BACE1) activity and protein expression. BACE1 is the primary enzyme responsible for the production and deposition of Aβ peptide. TA can also inhibit the in vitro aggregation of tau peptide, a core component of intracellular neurofibrillary tangles (NFTs). In addition, combination of tannic acid with eucalyptus Oil and Allantoin (from Comfrey) is known as homeopathic product which is used to temporarily relieve the aches and pains of muscles and joints associated with: arthritis, simple backache, strains, bruises, sprains.
Status:
US Previously Marketed
First marketed in 1921
Class:
MIXTURE
Status:
US Previously Marketed
First marketed in 1921
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT04160767: Phase 4 Interventional Unknown status Celiac Disease
(2019)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NDA021361
(2004)
Source URL:
First approved in 2004
Source:
NDA021361
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA076903
(2004)
Source URL:
First approved in 2004
Source:
ANDA076903
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA201676
(1999)
Source URL:
First approved in 1999
Source:
ANDA201676
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT01683565: Phase 4 Interventional Completed Preterm Birth
(2012)
Source URL:
First approved in 1999
Source:
21 CFR 352
Source URL:
Class:
MIXTURE